Advanced search
Publication Cover
Gynecological Endocrinology Volume 35, 2019 - Issue 5
Submit an article Journal homepage
192
Views
7
CrossRef citations to date
0
Altmetric
OVARIAN HYPER STIMULATION SYNDROME

Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome

Shevach FriedlerInfertility and IVF Unit, Barzilai University Medical Center, Ashkelon, Israel; ;Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel
&
Leonti GrinInfertility and IVF Unit, Barzilai University Medical Center, Ashkelon, Israel; ;Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, IsraelCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4552-4428
ORCID Icon
Pages 368-369 | Received 27 Jan 2018, Accepted 12 Nov 2018, Published online: 07 Jan 2019

References

  • van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154.
  • Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004;19:1176–1180.
  • Tesarik J, Hazout A, Mendoza-Tesarik R, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006;21:2572–2579.
  • Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod. 2005;20:1798–1804.
  • Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006;21:1894–1900.
  • Pirard C, Loumaye E, Laurent P, Wyns C. Contribution to more patientfriendly ART treatment: Efficacy of continuous low-dose GnRH agonist as the only luteal support—results of a prospective, randomized, comparative study. Int J Endocrinol. 2015;2015:1.
  • Youssef MAFM, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046.
  • Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril. 2015;103:879–885.
  • Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, et al. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril. 2016;106:330–333.
  • Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online. 2014; 29:274–280.
  • Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–2892.
  • Engmann L, DiLuigi A, Schmidt D, et al. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril. 2008;89:554–561.
  • Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006;13:173–178.
  • Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010;93:847–854.
  • Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and HCG-based, progesterone-free luteal support: a proof of concept study. Hum Reprod. 2011;26:2874–2877.
  • Andersen CY, Elbaek HO, Alsbjerg B, et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Hum Reprod. 2015;30:2387–2395.
  • Nastri CO, Teixeira DM, Moroni RM, et al. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45:377–393.
  • Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901–907.
  • Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;6:2593–2597.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.